SPY758.92+0.24%QQQ688.56+0.06%BTC/USD69,119.58−3.15%DIA523.45+0.19%GLD356.39+0.42%TLT79.37−0.44%

Viridian Therapeutics Inc

VRDNNASDAQ

Trade with Public

$30.48

-0.77-2.46%

At close: Nov 11, 4:00 PM EST

$30.35

-0.90-2.88%

Pre-Market: 7:44 AM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Viridian Therapeutics (VRDN) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Viridian Therapeutics (VRDN) stock.

Analyst Consensus — 17 Analysts

1S.Buy

15Buy

1Hold

# Analysts17

Latest Upgrades and Downgrades for Viridian Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Wedbush	Laura Chico	PT Raise	Outperform	$42→$44
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$34→$39
—	Leerink Partners	Thomas Smith	PT Raise	Outperform	$50→$54
—	RBC Capital	Lisa Walter	PT Raise	Outperform	$38→$41
—	Truist Securities	Gregory Renza	PT Raise	Buy	$39→$42
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$31→$34
—	Evercore ISI Group	Maneka Mirchandaney	PT Raise	Outperform	$26→$33
—	Wedbush	Laura Chico	PT Raise	Outperform	$41→$42
—	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$22→$40
—	Needham	Serge Belanger	PT Raise	Buy	$34→$38
—	RBC Capital	Lisa Walter	PT Raise	Outperform	$36→$38
—	RBC Capital	Lisa Walter	PT Raise	Outperform	$35→$36
—	Truist Securities	Gregory Renza	PT Raise	Buy	$38→$39
—	RBC Capital	Lisa Walter	PT Raise	Outperform	$34→$35
—	Truist Securities	Gregory Renza	PT Raise	Buy	$35→$38
—	Wedbush	Laura Chico	PT Raise	Outperform	$32→$43
—	Needham	Serge Belanger	PT Raise	Buy	$32→$34
—	Wells Fargo	Derek Archila	Upgrade	Equal-Weight→Overweight	$20→$31
—	Needham	Serge Belanger	Maintained	Buy	$32
—	Evercore ISI Group	Maneka Mirchandaney	PT Cut	Outperform	$27→$26

Viridian Therapeutics Inc

Viridian Therapeutics (VRDN) Stock Price Target 2026

Latest Upgrades and Downgrades for Viridian Therapeutics Stock

Viridian Therapeutics (VRDN) Stock Price Target 2026

Latest Upgrades and Downgrades for Viridian Therapeutics Stock

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39

PRO
Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39

PRO
Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34

Viridian Therapeutics Inc

Viridian Therapeutics (VRDN) Stock Price Target 2026

Latest Upgrades and Downgrades for Viridian Therapeutics Stock

Viridian Therapeutics (VRDN) Stock Price Target 2026

Latest Upgrades and Downgrades for Viridian Therapeutics Stock

Analyst Ratings News

PROWedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44

PROWells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39

PROLeerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54

PRORBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

PROTruist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

PROWells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34

People Also Watch

People Also Watch

Analyst Ratings News

PROWedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44

PROWells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39

PROLeerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54

PRORBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

PROTruist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

PROWells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39

PRO
Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39

PRO
Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42

PRO
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34